Anti-angiogenic agents used to target tumour neovascularization can be classified into two groups: agents binding the vascular endothelial growth factor (VEGF), such as the humanised monoclonal antibody (Mab) bevacizumab or the soluble decoy receptor VEGF Trap and second, the receptor tyrosine kinase inhibitors (TKIs) targeting the VEGF receptor family, such as sunitinib and sorafenib.

Bevacizumab has proven efficacy against several solid tumours ([Presta *et al*, 1997](#bib33){ref-type="other"}), amongst others against non-small cell lung cancer (NSCLC). A phase III study by [Sandler *et al* (2006)](#bib34){ref-type="other"} showed a survival benefit in advanced stage NSCLC patients when bevacizumab was combined with chemotherapy in first-line setting. This was recently confirmed by [Manegold *et al* (2008)](#bib27){ref-type="other"}. Moreover, a phase I/II trial combining the epidermal growth factor receptor (EGFR) inhibitor erlotinib or chemotherapy with bevacizumab resulted in higher response rates and longer median progression-free survival (PFS) in both bevacizumab containing arms ([Herbst *et al*, 2007](#bib16){ref-type="other"}).

The orally available anti-angiogenic TKI, sorafenib is a multi-targeted inhibitor of raf-kinase, VEGFR1, VEGFR2, VEGFR3, PDGFR-*β*, Flt3 and c-kit, which has been approved in the treatment of both advanced renal cell carcinoma and hepatocelullar carcinoma. There is an emerging evidence of clinical anti-tumour activity in NSCLC ([Gatzemeier *et al*, 2006](#bib14){ref-type="other"}; [Schiller *et al*, 2008](#bib35){ref-type="other"}).

Although anti-tumour activity is achieved by these anti-angiogenic drugs either as monotherapy or in combination with chemotherapy or with other targeted agents, it remains unclear which patient will benefit most from treatment ([Broxterman *et al*, 2009](#bib3){ref-type="other"}). Biomarkers that potentially predict treatment response, in order to guide patient selection and/or monitor early response, are currently being investigated ([Le Tourneau *et al*, 2008](#bib23){ref-type="other"}; [Pathak *et al*, 2008](#bib30){ref-type="other"}).

Particularly attractive biomarkers might be circulating endothelial cells (CECs), as these may reflect damage to the tumour vasculature or circulating haematopoietic progenitor cells (HPCs), as they have been proposed to reflect a pro-angiogenic cell population, which may respond to increased hypoxia by effective anti-angiogenic therapy ([Jain and Duda, 2003](#bib19){ref-type="other"}; [Shaked *et al*, 2006](#bib36){ref-type="other"}; [Zurita *et al*, 2009](#bib47){ref-type="other"}).

No studies are currently available assessing the effects of anti-angiogenic agents in NSCLC patients on CECs and HPCs. In this study we evaluated (1) changes in CECs, defined as CD34^bright^/CD45^−^/(VEGFR2^+^), and HPCs, defined as CD34^bright^/CD45^dim^/(CD133^+^), in NSCLC patients treated with anti-angiogenic therapy with sorafenib plus erlotinib (SO/ER); (2) we investigated the specificity of these changes by comparing these with a control group of patients receiving bevacizumab plus erlotinib (BV/ER) or monotherapy erlotinib, and (3) we correlated the changes of the biomarkers with treatment response in the SO/ER patient group.

Materials and methods
=====================

Patient and study design
------------------------

From November 2007 to October 2008 25 chemotherapy-naive patients with advanced NSCLC who were treated at the VU University Medical Center in a phase II trial combining erlotinib (150 mg day^−1^) and sorafenib (400 mg twice daily) were enrolled in this study ([Lind *et al*, 2009a](#bib24){ref-type="other"}).

For comparison, a cohort of 18 NSCLC patients treated with bevacizumab (15 mg kg^−1^ intravenously every 21 days) plus erlotinib (150 mg day^−1^ orally) in a phase II trial ([Groen *et al*, 2007](#bib15){ref-type="other"}) and a control group of 10 patients treated with whole brain radiotherapy (WBRT) plus concurrent erlotinib for brain metastases from NSCLC in phase I trial were evaluated ([Lind *et al*, 2009b](#bib25){ref-type="other"}). These control group patients received erlotinib 1 week before and during WBRT (30 Gy in 10 once-daily fractions) and continued maintenance erlotinib (150 mg day^−1^) until unacceptable toxicity or disease progression.

Before study entry, all patients provided written informed consent in accordance with the national and institutional guidelines, which strictly adhere to the principles of the Declaration of Helsinki and ICH/Good Clinical Practice.

Peripheral blood (PB) was taken from all patients on three occasions: before start of treatment, day (D) 0, and 7 and 21 days after starting drug treatment, D7 and D21, respectively. Computed tomography was carried out before and 6 weeks after the start of treatment to assess clinical response according to the Response Evaluation Criteria in Solid Tumors (RECIST) ([Therasse *et al*, 2000](#bib38){ref-type="other"}). In the SO/ER-treated patients response incorporating primary tumour cavitations, as proposed by [Crabb *et al* (2009)](#bib6){ref-type="other"}, were also determined. Clinical responses after 6 weeks of treatment were used to examine a possible relation with VEGF and erythropoietin (EPO, in SO/ER-treated patients only) levels and the cellular biomarkers.

Evaluation of cells and plasma biomarkers
-----------------------------------------

Blood from SO/ER-treated patients was collected in EDTA tubes and the circulating HPCs and CECs were measured using a full-blood flow cytometric method as previously described ([Vroling *et al*, 2007](#bib43){ref-type="other"}, [2009](#bib42){ref-type="other"}). (CD133^+^) HPCs were defined as CD34^bright^/CD45^dim^ (and CD133^+^) and CECs were defined as CD34^bright^/CD45^neg^ and largely positive for VEGFR2. The antibodies used to carry out analysis in this study included CD45--FITC, CD34--APC, CD133--PE, VEGFR2--PE and viability marker 7-AAD. Cell populations were measured by flow cytometry (FACSCalibur, BD Bioscience, Breda, The Netherlands) in a total volume of 1.5 ml full blood and appropriate IgG isotypes were used as a control. Circulating cells from the comparison groups (monotherapy erlotinib and BV/ER) were assessed with CD45--FITC, CD34--APC and 7-AAD. Cell populations of the total white blood cells (WBC) were calculated as number ml^−1^ of blood using blood cell count measured on a Sysmex. EDTA blood was used for the collection of plasma, which was stored at −80°C until further analysis. Plasma VEGF and EPO levels were measured in duplicate with the enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA).

Statistical analyses
--------------------

Circulating cell populations (numbers ml^−1^), plasma levels of VEGF (pg ml^−1^) and EPO (mIU ml^−1^) were expressed as median (range). Continuous variables between groups were compared with Mann--Whitney *U*-test. To compare the blood-based parameters at pre-treatment with those during treatment (D0, D7 and D21) the Wilcoxon\'s signed-rank test was used. Time-to-progression (TTP) was determined as the time period from start of treatment to the time of documented disease progression with a minimum follow-up period of 6 months. Overall survival (OS) was the time between the first day of treatment and the date of death or the date on which patients were last known to be alive. Correlations of the circulating cells with TTP and overall OS were determined with the Kaplan--Meier method and its associated log-rank statistic. Responders were defined as those achieving partial response (PR) according to RECIST and non-responders as those with stable disease (SD) or progressive disease (PD) after 6 weeks of treatment. Differences were considered statistically significant when *P*\<0.05 (two-tailed). As this was an exploratory study, no correction for multiple testing was done. Statistical analyses were carried out with SPSS (SPSS for Windows 15.0, SPSS, Chicago, IL, USA) software programme.

Results
=======

Patient characteristics and treatment response
----------------------------------------------

In total, 53 NSCLC patients in three study groups were investigated. Patients treated with SO/ER included in this study (14 males and 11 females) had a median age of 60 years (range 41--78) at the start of treatment. The clinical response of patients was assessed using RECIST criteria ([Therasse *et al*, 2000](#bib38){ref-type="other"}). Thirteen out of the 25 SO/ER-treated patients had developed cavitations in the primary tumour at week 6 of evaluation. For these patients, responses incorporating cavitations were also correlated with the circulating cells and plasma parameters. Patients treated with SO/ER had a median TTP of 6 months (range 0.82--12.7) and an OS of 12.4 months (range 2.3--16.0). Patients treated with BV/ER had a median TTP of 6.8 months (range 3.2--10.3) and an OS of 6.9 months (range 5.4--8.3). Further, patient and tumour characteristics are summarised in [Table 1](#tbl1){ref-type="table"}.

Definitions of HPCs and CECs populations
----------------------------------------

The FACS analysis of a blood sample of a representative patient from the study is shown in [Figure 1](#fig1){ref-type="fig"}. As described previously for renal cell cancer patients ([Vroling *et al*, 2009](#bib42){ref-type="other"}), two distinct CD34^+^ cell populations, which differ in the expression of the leucocyte marker CD45 and progenitor marker CD133, were identified in NSCLC patients. HPCs are the CD45^dim^/CD34^bright^ cells, which are largely CD133^pos^. The cutoff value for CD133 positivity in HPCs was determined based on isotype control and was adjusted for every individual sample. CECs are CD34^bright^, which are almost uniformly positive for VEGFR2, but lack both markers CD45 and CD133 as previously defined ([Vroling *et al*, 2007](#bib43){ref-type="other"}, [2009](#bib42){ref-type="other"}) ([Figure 1](#fig1){ref-type="fig"}).

Marked decrease of HPCs during treatment with TKI sorafenib
-----------------------------------------------------------

The total WBC count showed little change during treatment with SO/ER, BV/ER or monotherapy erlotinib ([Figure 2A](#fig2){ref-type="fig"}). Although no leucopenia was observed during any of the treatment regimens, we found a marked decrease of HPCs ([Figure 2B](#fig2){ref-type="fig"}) after 7 days of treatment with SO/ER (median from 1345 cells ml^−1^ at D0 to 511 cells ml^−1^ on D7, *P*\<0.001), which decreased further after 3 weeks of treatment (to a median of 356 cells ml^−1^, *P*\<0.0001). The sub-population of CD133^+^/HPCs also showed a similar decrease (from 1086 cells ml^−1^ at D0 to 361 cells ml^−1^ on D7 (*P*\<0.0001) to 264 cells ml^−1^ on D21 (*P*\<0.0001)). In the patient groups, treated with either BV/ER or monotherapy erlotinib, the HPC numbers did not change significantly ([Figure 2B](#fig2){ref-type="fig"}).

Anti-angiogenic treatment-specific increase of CECs
---------------------------------------------------

Patients treated with SO/ER showed an increase in the number of CECs, which was also found in patients treated with BV/ER but not with monotherapy erlotinib ([Figure 2C](#fig2){ref-type="fig"}). SO/ER-treated patients showed a three-fold increase in CECs on D7 (median, from 41 to 124 cells ml^−1^, *P*=0.001) and BV/ER-treated patients more than a two-fold increase in CECs (median, from 59 to 132 cells ml^−1^, *P*=0.002). CECs during monotherapy erlotinib did not change after 7 days of treatment (median, from 48 to 51 cells ml^−1^, *P*=0.8). The VEGFR2 positive fraction of CECs enumerated in SO/ER-treated patients followed the same trend as total CECs ([Figure 2D](#fig2){ref-type="fig"}). In both patient groups treated with either a TKI or anti-VEGF, Mab-angiogenesis inhibitor CECs further increased after 3 weeks of treatment in contrast to patients treated with monotherapy erlotinib ([Figure 3](#fig3){ref-type="fig"}).

Response and biomarkers
-----------------------

In order to analyse the possible relations of biomarker values with response we used RECIST criteria and RECIST criteria taking into account tumour cavitations as recently suggested by [Crabb *et al* (2009)](#bib6){ref-type="other"}. CD133^+^/HPCs were not significantly correlated with the response when RECIST was not adjusted for tumour cavitations. When the response was corrected for cavitations, pre-treatment levels of CD133^+^/HPCs but not the total HPCs, were significantly lower in responding (PR) patients compared with non-responding (SD+PD) patients treated with SO/ER (*P*=0.01 and *P*=0.28 respectively, [Figure 4A](#fig4){ref-type="fig"}). Nine out of 12 patients with lower than the median of 1086 CD133^+^/HPCs ml^−1^ and 4 out 12 with higher than the median of CD133^+^/HPCs showed a response (PR). Patients with low CD133^+^/HPCs (lower than the median of 1086 cells ml^−1^) had a significantly longer TTP than those with CD133^+^/HPCs higher than the median pre-treatment levels, which was again not seen for the total population of HPCs (*P*\<0.05 and *P*=0.334 respectively, [Figure 4B](#fig4){ref-type="fig"}). TTP was calculated from RECIST not corrected for tumour cavitations, as this is currently not validated. At the time of analyses CD133^+^/HPCs did not correlate with OS. Pre-treatment CECs or changes in CECs after 7 or 21 days in patients treated with SO/ER did not correlate with TTP, OS or response (according RECIST) with or without adjustments for cavitations. The latter was comparable for patients treated with BV/ER.

Plasma VEGF and EPO levels in NSCLC patients
--------------------------------------------

Patients treated with SO/ER showed a slight non-significant increase in plasma VEGF during 21 days of treatment ([Figure 5A](#fig5){ref-type="fig"}), which was similar in patients treated with monotherapy erlotinib (data not shown). BV/ER-treated patients showed a significant decrease in plasma VEGF levels after 7 days (median decreased from 134 to 25 pg ml^−1^, *P*=0.002, data not shown), probably because the used ELISA-kit measures only free VEGF ([Loupakis *et al*, 2007](#bib26){ref-type="other"}). No correlation was found between pre-treatment plasma VEGF levels and treatment outcome. Moreover, we found no significant relationship between the (VEGFR2^+^) CECs, (CD133^+^) HPCs and pre-treatment plasma VEGF in any patient group (data not shown).

To investigate if plasma EPO levels can serve as a surrogate pharmacodynamic biomarker or may have a possible relation with CECs and HPCs the plasma EPO levels were determined in the SO/ER-treated patients. Minor changes in plasma EPO were observed (median, from 6.5 on D0 to 6.6 on D7 to 7.8 mIU ml^−1^ on D21, [Figure 5B](#fig5){ref-type="fig"}) which were all in the normal range of EPO levels (3.1--14.9 mIU ml^−1^). Pre-treatment plasma EPO levels showed no correlation with circulating cell numbers or patient response (data not shown).

Discussion
==========

We monitored, to our knowledge for the first time, VEGFR2-positive circulating endothelial cells and CD133-positive haematopoietic progenitor cells in NSCLC patients treated with the anti-angiogenic agent SO combined with ER. The second objective of the study was to provide data on the specificity of the measured changes in CECs and HPCs for SO/ER treatment. For this purpose data from two smaller groups of patients were obtained. The most important findings we report here are: VEGFR2^+^ CECs increase in an anti-VEGF treatment-specific manner, with a similar two- to three-fold increase (on D7 or D21) after treatment with the VEGFR--TKI sorafenib or anti-VEGF antibody bevacizumab, both combined with the EGFR--TKI erlotinib, but not with erlotinib monotherapy (see [Figure 2C](#fig2){ref-type="fig"}).CD133^+^/HPCs markedly decreased with \>60% on D7 and about 75% on D21 of treatment with SO/ER. This effect is not seen during treatment with BV/ER or monotherapy erlotinib with whole brain radiotherapy.The pre-treatment CD133^+^/HPC numbers predicted for response incorporating tumour cavitations to SO/ER therapy. In addition, TTP defined by RECIST was significantly longer in the patient group with a lower than median number of CD133^+^ HPCs.

Circulating endothelial cells are a very rare cell population, normally defined as mature endothelial cells shed from the vasculature and are considered to be a useful biomarker of vascular damage ([Willett *et al*, 2004](#bib44){ref-type="other"}; [Duda *et al*, 2006](#bib9){ref-type="other"}; [Batchelor *et al*, 2007](#bib2){ref-type="other"}; [Norden-Zfoni *et al*, 2007](#bib29){ref-type="other"}). In addition, the possibility to monitor circulating endothelial progenitor cells (CEPs) has been proposed as an attractive biomarker for anti-angiogenic agents after the seminal identification of circulating progenitors, which could grow out to highly proliferative endothelial outgrowth cells (EOCs) ([Ingram *et al*, 2005](#bib18){ref-type="other"}; [Shaked *et al*, 2006](#bib36){ref-type="other"}). Although originally CEPs were discriminated from mature CECs mainly by the presence or absence of CD133 progenitor markers, more recent data have cast serious doubts on this premise ([Timmermans *et al*, 2008](#bib39){ref-type="other"}; [Yoder and Ingram, 2009](#bib45){ref-type="other"}).

The population of CECs that we have monitored has a phenotype consistent with a population containing the precursor for EOCs, namely CD34^+^, VEGFR2^+^, but CD45^−^ and CD133^−^ (see [Figure 1](#fig1){ref-type="fig"}) according to [Case *et al* (2007)](#bib5){ref-type="other"} and [Timmermans *et al* (2007)](#bib40){ref-type="other"}. However, whether CECs are a mixed mature/progenitor population will only be determined once these very rare cells can be sorted after a unique specific marker of the endothelial progenitor cell will have been identified ([Yoder and Ingram, 2009](#bib45){ref-type="other"}).

In this study, the CEC population did not predict for response to SO/ER or BV/ER therapy. Regarding the explanations for the lack of correlation between pre-treatment values or increases in CECs and response one can only speculate. Our finding of an increase in CECs in SO/ER or BV/ER, but not monotherapy erlotinib-treated patients is consistent with our earlier finding of a similar increase in renal cell cancer patients treated with the VEGFR--TKI sunitinib ([Vroling *et al*, 2009](#bib42){ref-type="other"}). Therefore, the increase of this cell population is likely to be a pharmacodynamic marker for VEGF/VEGFR signalling-inhibitor therapy.

Preclinical and early clinical data (phase I and phase II trials) have supported combined inhibition of VEGFR and EGFR pathways in NSCLC ([Pennell and Lynch, 2009](#bib31){ref-type="other"}). Activating EGFR mutations are predictive of response to EGFR inhibitors with reported response rates of upto 75%. In the specific group studied here, six out of eight (75%) patients with an activating EGFR mutation showed a response (PR). Of the WT EGFR group 6 out of 13 (46%) patients showed a response (PR). This is higher than the rates reported for erlotinib monotherapy and implies a significant contribution of sorafenib on the clinical outcome with this combination treatment. The currently identified CD133^+^ progenitor cell population might be of help in future evaluation of this type of combination therapy.

Unlike CECs, the total HPC population showed a marked decrease during SO/ER treatment in contrast to patients treated with BV/ER or monotherapy erlotinib with WBRT. Such a decrease of the HPCs also occurs in RCC patients treated with sunitinib ([Vroling *et al*, 2009](#bib42){ref-type="other"}) and might be related to the Flt-3 inhibitory effects of both TKI sorafenib and sunitinib, as Flt3-signalling is required for HPC proliferation and mobilisation into the circulation ([Gabbianelli *et al*, 1995](#bib12){ref-type="other"}; [Faivre *et al*, 2007](#bib11){ref-type="other"}; [Kumar *et al*, 2009](#bib22){ref-type="other"}). In this study, the pre-treatment level of the CD133^+^/HPCs was significantly higher in the non-responders to SO/ER therapy, and the group with higher than median CD133^+^/HPC values showed a shorter TTP. Also, the decrease in CD133^+^/HPCs on D7 was much smaller in patients with longer TTP (data not shown), which may be a reflection of the lower HPC mobilisation from the bone marrow into the circulation in those patients. Although the inhibition of circulating HPC numbers is very likely a pharmacological effect of sorafenib, the correlation with the anti-tumour effect (of the sorafenib plus erlotinib combination) may or may not be indicative of a role of this population in tumour growth. In contrast to the hypothesised effects of populations of circulating endothelial progenitors, a pro-angiogenic role of HPCs and CD133^+^ sub-populations of HPCs recruited from the bone marrow to hypoxic or tumour tissues ([Kerbel, 2008](#bib21){ref-type="other"}; [Burt *et al*, 2009](#bib4){ref-type="other"}) is consistently reported. Thus, there is wide agreement on the positive role of CD133^+^/CD34^bright^/CD45^dim^ HPCs in (tumour) adult neovascularization. The ongoing debate is on the evidence for the existence in the adult of bone marrow-derived progenitors for potent long-term endothelial layer forming cells in addition to the progenitors for cell populations that promote tumour neovascularization indirectly by secreting growth factors. However, present studies point to a limited incorporation of bone marrow-derived cells into the endothelium of tumours ([Peters *et al*, 2005](#bib32){ref-type="other"}). Many recent studies and reviews discuss the properties of pro-angiogenic cell populations or 'circulating angiogenic cells\' in depth ([Case *et al*, 2007](#bib5){ref-type="other"}; [Timmermans *et al*, 2007](#bib40){ref-type="other"}, [2008](#bib39){ref-type="other"}; [Hirschi *et al*, 2008](#bib17){ref-type="other"}; [Gao *et al*, 2009](#bib13){ref-type="other"}; [Yoder and Ingram, 2009](#bib45){ref-type="other"}).

A specific role of CD133^+^/HPCs has been suggested in pulmonary vascular remodelling in patients with obstructive pulmonary disease ([Asosingh *et al*, 2008](#bib1){ref-type="other"}) or idiopathic pulmonary arterial hypertension ([Diez *et al*, 2007](#bib7){ref-type="other"}). Thus, it seems plausible that the production and release of cytokines, chemokines and proteolytic enzymes (VEGF, SDF-1 and metalloproteases) by the lung tumour tissue will increase the mobilisation of CD133^+^/HPCs from the bone marrow, which may be home to hypoxic tumour tissue and have a fundamental role in tumour neovascularization and progression ([Kerbel, 2008](#bib21){ref-type="other"}; [Shojaei and Ferrara, 2008](#bib37){ref-type="other"}).

In this scenario, part of the anti-tumour effect of sorafenib, but also sunitinib, may be related to the suppression of mobilisation of (CD133^+^) HPCs from the bone marrow. Other studies also suggest that high numbers of circulating CD133^+^/HPCs are related to a worse outcome in cancer patients. CD133 mRNA from PB cells, which is predominantly derived from the HPCs was shown to be an independent prognostic factor for patient survival ([Mehra *et al*, 2006](#bib28){ref-type="other"}).

A very recent study showed that higher pre-treatment levels of CD133^+^/CD34^+^/CD45^dim^ cells (called circulating progenitor cells in that study) were associated with the worst outcome of suntinib therapy in hepatocellular carcinoma ([Zhu *et al*, 2009](#bib46){ref-type="other"}).

Altogether, these results fit with the concept of the pro-angiogenic capacity of HPCs in tumour neovascularization and might indicate a causative role of the suppression of these cells by the anti-angiogenic TKIs sorafenib and/or sunitinb to their anti-tumour effects and patient responses. As this cell population is well defined, it is also amenable to analysis at the RNA level in PB mononuclear cells.

In addition, plasma levels of VEGF and EPO (representing a larger repertoire of cytokines/growth factors) are known to be increased in mice or patients upon treatment with anti-VEGF therapy ([Ebos *et al*, 2007](#bib10){ref-type="other"}; [Vroling *et al*, 2009](#bib42){ref-type="other"}) and have early on been considered as candidate biomarkers for the effectivity of this type of therapy. In this study, VEGF and EPO, were not predictive of response or TTP to SO/ER-combination therapy. [Dowlati *et al* (2008](#bib8){ref-type="other"}) found that VEGF was predictive for response in NSCLC patients treated with bevacizumab, but no relation was found with survival.

An important difficulty in defining or identifying biomarkers is the evaluation of the endpoint of the actual responses of the patients. RECIST is the most widely used method for assessing the responses of patients ([Therasse *et al*, 2000](#bib38){ref-type="other"}), but has been critically updated by [Karrison *et al* (2007)](#bib20){ref-type="other"} and [Verweij *et al* (2009)](#bib41){ref-type="other"}. In addition [Crabb *et al* (2009)](#bib6){ref-type="other"} suggest that response assessment might be improved in NSCLC patients, treated with angiogenesis inhibitors, by incorporating cavitation into volume assessment for target lesions potentially altering treatment outcomes. In that study, marked pulmonary cavitation occurred in 24% of patients treated with the angiogenesis inhibitor cediranib plus chemotherapy, which was not seen with chemotherapy alone. Our sorafenib data suggest that correcting for cavitations may be of importance in evaluating potential biomarkers in relation to response. In SO/ER-treated patients 13 out of 25 patients had cavitations because of the treatment. Incorporating these cavitations in response assessment altered the RECIST responses. Pre-treatment numbers of CD133^+^/HPCs were only prognostic for the response if corrected for cavitations.

In our study, several cell populations and plasma markers were evaluated to serve as a potential biomarker during anti-angiogenesis treatment. This introduces the potential problem of multiple testing, which increases the risk to find false-positive relations. Clearly, our study was designed to explore associations that should be confirmed in an independent group of patients.

In conclusion, CECs increased in NSCLC patients treated with SO/ER and BV/ER, but not with erlotinib monotherapy. Thus, this effect can be ascribed to the anti-angiogenic agents. The CD133^+^/HPCs decreased significantly in all patients treated with SO/ER and pre-treatment numbers were significantly lower in responding patients and pre-treatment CD133^+^/HPC numbers correlated with the TTP. CD133^+^/HPCs may therefore be considered for further investigations as a biomarker for selecting patients who are likely to benefit from SO/ER.

This study was supported by the European Union (FP6) Integrated project 'Angiotargeting\' (contract no. 504743). We thank Atie van Wijk for her help with patient care.

![Full blood analysis of circulating endothelial cells (CECs) and haematopoietic progenitor cells (HPCs) in a non-small cell lung cancer (NSCLC) patient. (**A**) Detection of total CECs and HPCs based on marker expression of CD45 and CD34. CECs by CD45^neg^/CD34^bright^ and HPCs defined by CD45^dim^/CD34^bright^. (**B**) Expression of VEGFR2 and CD133 on CECs and HPCs as indicated by the boxes.](6605477f1){#fig1}

![Blood cell populations during anti-angiogenic treatment. (**A**) The total white blood cell (WBC) levels show little change during treatment with sorafenib plus erlotinib (SO/ER) and bevacizumab plus erlotinib (BV/ER). (**B**) Although BV/ER and ER treatment do not show a decrease in viable haematopoietic progenitor cell (HPC) numbers, treatment with tyrosine kinase inhibitor (TKI) SO/ER shows a significant marked depression of the viable HPCs after D7 (*P*\<0.001) and D21 (*P*\<0.001). (**C**) TKI SO and monoclonal antibody (Mab) BV combined with ER lead to an increase in viable circulating endothelial cells (CECs) after D7 (*P*\<0.01 and *P*\<0.01, respectively) and further increased after D21 (*P*\<0.001 and *P*\<0.01, respectively), which was not observed with monotherapy ER. (**D**) The viable CD133^+^/HPCs and VEGFR2^+^/CECs sub-populations measured in SO/ER patients showed a respective decrease and increase in parallel to the total population of HPCs and CECs. ^\*^*P*\<0.05, ^\*\*^*P*\<0.001.](6605477f2){#fig2}

![Specificity of increase in circulating endothelial cells (CECs). Anti-angiogenic treatment with direct VEGFR tyrosine kinase inhibitor (TKI) sorafenib, as well as indirect vascular endothelial growth factor (VEGF) withdrawal by monoclonal antibody (Mab) bevacizumab in combination with anti-epidermal growth factor receptor (EGFR) inhibitor erlotinib showed an increase in CECs after 7 days and 21 days of treatment. No change in CEC numbers was observed in control patients treated with TKI erlotinib. ^\*^*P*\<0.01, ^\*\*^\<0.001.](6605477f3){#fig3}

![Boxplots and Kaplan--Meier curves, according to peripheral blood circulating CD133^+^/haematopoietic progenitor cells (HPCs) in sorafenib plus erlotinib (SO/ER)-treated non-small cell lung cancer (NSCLC) patients. (**A**) Mean pre-treatment numbers of CD133^+^/HPC of non-responders (*n*=11) and responders (*n*=13). Responses are according to Response Evaluation Criteria in Solid Tumors (RECIST) incorporated cavitations. ^\*^=*P*\<0.05. (**B**) Time-to-progression (TTP) according to RECIST correlated with pre-treatment CD133^+^/HPCs and the total population of HPCs with a median cutoff value of 1086 and 1345 cells ml^−1^, respectively. 'Low\' indicates (CD133^+^)/HPCs at baseline below the median and 'high\' indicates (CD133^+^)/HPCs at baseline higher than the median.](6605477f4){#fig4}

![Plasma vascular endothelial growth factor (VEGF) and erythropoietin (EPO) levels in non-small cell lung cancer (NSCLC) patients treated with SO/ER. (**A**) Free plasma VEGF levels (pg ml^−1^) did not change significantly during 21 days of sorafenib plus erlotinib (SO/ER) (*n*=25). ^\*^*P*\<0.01. (**B**) Plasma EPO levels (mIU ml^−1^) in NSCLC patients showed a slight increase during sorafenib treatment. (D21, ^\*^*P*\<0.01).](6605477f5){#fig5}

###### 

Patient characteristics and response to treatment at 6 weeks

  **Characteristic**                                     **SO/ER**          **BV/ER**          **ER**
  ------------------------------------------------- ------------------- ----------------- -----------------
  Total                                                     25                 18                10
                                                                                                   
  *Sex*                                                                                   
   Male                                                   14 (44)            12 (67)           4 (40)
   Female                                                 11 (56)            6 (33)            6 (60)
  Median age (years) (range)                            60 (41--78)        63 (34--80)       68 (59--77)
                                                                                                   
  *Smoking status*                                                                        
   Current or former smoker                               20 (80)           18 (100)           9 (90)
   Non-smoker                                             5 (20)                0              1 (10)
                                                                                                   
  *ECOG performance status*                                                               
   0                                                      17 (68)            5 (28)            2 (20)
   1                                                      8 (32)             9 (50)            7 (70)
   2                                                         0               4 (22)            1 (10)
                                                                                                   
  *Tumour histology*                                                                      
   Adenocarcinoma                                         18 (72)            12 (67)           5 (50)
   Large cell                                              2 (8)             5 (28)            4 (40)
   Squamous cell                                           1 (4)                0              1 (10)
   BAC                                                     2 (8)              1 (6)               0
   NSCLC NOS                                               2 (8)                0                 0
                                                                                                   
  *Tumour stage*                                                                          
   IIIB                                                   7 (28)             5 (28)            1 (10)
   IV                                                     18 (72)            13 (72)           9 (90)
                                                                                                   
  *Previous treatment*                                                                    
   Yes                                                     2 (8)                0              5 (50)
   No                                                     23 (92)           18 (100)           5 (50)
                                                                                                   
  *Response at 6 weeks*                                                                   
   Partial response                                       10 (40)            4 (22)               0
   Stable disease                                         12 (48)            10 (56)           8 (80)
   Progressive disease                                   3 (12)^a^           4 (22)            2 (20)
                                                                                                   
  *Response at 6 weeks corrected for cavitations*           ---                ---        
   Partial response                                       13 (52)                                  
   Stable disease                                         9 (36)                                   
   Progressive disease                                   2 (8)^a^                                  
                                                                                                   
  Median time to progression, months (95% CI)        6.0 (11.7--13.2)    6.8 (3.2--10.3)   6.6 (2.6--10.7)
  Median survival, months (95% CI)                   12.5 (11.7--13.2)   6.9 (5.4--8.3)     6.0 (0--12.8)

Abbreviations: BAC=bronchioloalveolar carcinoma; BV=bevacizumab; ECOG=Eastern Cooperative Oncology Group; ER=erlotinib; SO=sorafenib.

One PD patient had no formal evaluation for treatment response because of early off study due to treatment-related toxicity.
